Portal de Periódicos da CAPES

Renal Denervation: A Review

2022; Elsevier BV; Volume: 80; Issue: 4 Linguagem: Inglês

10.1053/j.ajkd.2022.03.015

1523-6838

Jimena Rey-García, Raymond R. Townsend,

Renal and Vascular Pathologies

RDN, regardless of approach, remains a research-only procedure in the United States. The BP-lowering efficacy of RDN appears similar to those of many single-agent antihypertensive medications. The safety profile of RDN, an invasive procedure, has remained at an acceptable level to date. In the absence of unanticipated findings in the pending trials, we anticipate that RDN could one day be an added to the antihypertensive toolbox.